Programme Category
Programme Name
Programme Description
The Programme aims to improve and promote health in the Union to reduce the burden of communicable and non-communicable diseases by:
- protecting people from serious cross-border health threats
- improving the availability, accessibility and affordability of medicines, medical devices and other crisis-related products in the EU
- strengthening national health systems
Identifier Code
Call
Summary
This action aims to diversify and advance the pipeline of BSA candidates. More specifically, it will support the development and further characterisation of broad-spectrum antivirals targeting identified HERA priority viral families, which largely can be divided among respiratory RNA viral families, such as Paramyxo -, Orthomyxo and Coronaviridae, as well as those targeting viral families known for causing viral haemorrhagic fever (VHF), such as Arena-, Bunya-, Flavi -, Filoviridae.
Detailed Call Description
This action supports the policy priority to be better prepared to respond to serious cross-border health threats. It contributes to the achievement of the EU4Health Programme’s general objective of protecting people in the Union from serious cross-border threats to health and strengthening the responsiveness of health systems and coordination among the Member States to cope with serious cross-border threats to health.
The action aims to identify a potent BSA candidate, in order to advance its clinical development. A robust pipeline should contain multiple BSA candidates for each viral family that are developed in parallel. When selecting the BSA candidate, attention will be paid to the complementarity with existing Horizon Europe projects.
The proposal would need to cover early safety and efficacy trials for testing new or improved anti-viral therapeutics, with a clear regulatory and clinical pathway, including first in humans.
Innovative delivery systems and suitable safety profiles for broad use should be considered when possible as well as the application of novel approaches and widely applicable workflows (e.g. artificial intelligence) for rapid and reliable identification of broad-spectrum anti-viral therapeutics.
Call Total Budget
Financing percentage by EU or other bodies / Level of Subsidy or Loan
60%
You can apply for a higher project funding rate (80%) if your project is of ‘exceptional utility’ (further details in the call document p.32).
Indicative project budget: €10.000.000
Thematic Categories
- Health
- Research, Technological Development and Innovation
Eligibility for Participation
- Businesses
- International Organisations
- Legal Entities
- Private Bodies
- Researchers/Research Centers/Institutions
- State-owned Enterprises
Eligibility For Participation Notes
In order to be eligible, the applicants (beneficiaries and affiliated entities) must:
- be legal entities (public or private bodies)
- be established in one of the eligible countries, i.e.:
- EU Member States (including overseas countries and territories (OCTs)
- eligible non-EU countries:
- listed EEA countries and countries associated to the EU4Health Programme (list of participating countries)
Call Opening Date
Call Closing Date
National Contact Point(s)
Ministry of Health, Department of European Affairs
Ms MAKRIGIORGI Elena
Email: emakrigiorgi@moh.gov.cy
EU Contact Point
For help related to this call, please contact: HaDEA-HP-CALLS@ec.europa.eu